Global Lipid-Lowering Therapy Market By Drug Type (Statins – Atorvastatin (Lipitor), Cerivastatin (Baycol), Fluvastatin (Baycol), Lovastatin (Mevacor), Pravastatin (Pravachol), Simvastatin (Zocor), Others, Bile acid sequestrants, Niacin, Icosapent ethyl, Bempedoic acid, PCSK9 Inhibitors, Others); By Route or administration (Oral, Subcutaneous); By Age Group (55 years or younger, 56 – 60 years, 61 – 65 years, 66 – 70 years, 71- 75 years, older than 75 years); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
In terms of CAGR, the global lipid-lowering therapy market is growing at an estimated rate of 15.4% over the forecast period. Obesity is one of the biggest issues faced by this planet. Several factors like sedentary lifestyle, and consumption of junk food are causing people to gain weight. Gaining weight results in numerous health issues like cardiovascular diseases, strains on joints etc. Lipids happen to a broad group of molecules that occur naturally in a human body and include fats, sterols, and vitamins like vitamins A, D, E and K that are fat-soluble, monoglycerides, waxes, diglycerides, phospholipids, and others. Meanwhile major job of lipids is to storing energy, provide signal, and act just like structural components of cell membranes. Lipids are being extensively used by the cosmetic and food industries in nanotechnology. Also the healthcare sector is using it to resolve several health-related issues. Lipid-lowering therapy is one such treatment that is used extensively. It is being used to bring down the risk of atherosclerotic cardiovascular disease (ASCVD), with the help of statins. The global lipid-lowering therapy is growing at a rapid rate in present times.
The growth of the global lipid-lowering therapy market remained unaffected during the period of coronavirus pandemic. In fact, the number of sales made by this market went up. Lipid metabolism plays a key role when it comes to viral infections. The demand for lipid-lowering drugs like NPC1L1 inhibitior, HMGCR inhibitiors, and PCSK9 inhibitiors skyrocketed.
Drug Type Outlook
On the basis of offering, the global lipid-lowering therapy market has been divided into Statins, Bile acid sequestrants, Niacin, Icosapent ethyl, Bempedoic acid, PCSK9 Inhibitors and Others. The statins segment is further bifurcated into Atorvastatin (Lipitor, Cerivastatin (Baycol), Fluvastatin (Lescol), Lovastatin (Mevacor), Pravastatin (Pravachol), Simvastatin (Zocor) and others. Statins, more commonly known as HMG-CoA reductase inhibitors, happen to be a class of lipid-lowering drugs that bring down the illness and mortality in people possessing high risk of cardiovascular disease. These are the most used medications to reduce the levels of the cholesterol.
Global Lipid-Lowering Therapy Market Revenue & Forecast, (US$ Million), 2022 – 2030
Route of Administration Outlook
On the basis of route of administration, the global lipid-lowering therapy market has been categorised into oral and subcutaneous. The subcutaneous way of administration happen to be the most effective way of administering these drugs. In this method, a short needle is brought in the use to inject statins into the tissue layer located in the middle of the skin and the muscle. Meanwhile, the oral route is also gaining popularity and will see growth at the fastest rate.
Age Group Outlook
The age group segment of the global lipid-lowering therapy market has been bifurcated into 55 years or younger, 56 – 60 years, 61 – 65 years, 66 – 70 years, 71 – 75 years, and older than 75 years. Currently people in the age group of 56 – 60 years are rapidly opting for lipid-lowering therapies as these they face several issues like rise in the levels of cholesterol. On the other hand, the age group 55 years or younger is forecasted to witness growth at the fastest rate owing to changing lifestyle.
Region Outlook
On the basis of region, the Global Lipid-Lowering Therapy Market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the Europe has been accumulating majority of money for this market. Changing lifestyle along with higher consumption of unhealthy or junk food in various European nations is the reason why this market dominates.
Competitive Landscape
The report provides both, qualitative and quantitative research of global lipid-lowering therapy market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
A few of the key companies having operations in the global lipid-lowering therapy market are listed below:
- Akums Drugs & Pharmaceuticals Ltd
- Alnylam Pharmaceuticals
- Amgen Inc.
- AstraZeneca
- Merck & Co
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Sun Pharmaceutical Industries
- Other Market Participants
Global Lipid-Lowering Therapy Market
By Drug Type
- Statins
- Atorvastatin (Lipitor)
- Cerivastatin (Baycol)
- Fluvastatin (Lescol)
- Lovastatin (Mevacor)
- Pravastatin (Pravachol)
- Simvastatin (Zocor)
- Others
- Bile acid sequestrants
- Niacin
- Icosapent ethyl
- Bempedoic acid
- PCSK9 Inhibitors
- Others
By Route of Administration
- Oral
- Subcutaneous
By Age Group
- 55 years or younger
- 56 – 60 years
- 61 – 65 years
- 66 – 70 years
- 71 – 75 years
- Older than 75 years
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 - 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Lipid-Lowering Therapy Market
6. Market Synopsis:Â
Lipid-Lowering Therapy Market
7. Lipid-Lowering Therapy Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Lipid-Lowering Therapy Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Lipid-Lowering
Therapy Market
7.6. Impact of Covid-19 on Lipid-Lowering Therapy Market
8. Global Lipid-Lowering Therapy Market Analysis and Forecasts, 2022
- 2030
8.1. Overview
8.1.1. Global Lipid-Lowering Therapy Market Revenue (US$ Mn)
8.2. Global Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
8.2.1. Statins (Definition, Market Estimation and Penetration, 2015 -
2021, Market Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound
Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific,
Middle East and Africa, Latin America) and Information on Atorvastatin
(Lipitor), Cerivastatin (Baycol), Fluvastatin (Lescol), Lovastatin (Mevacor),
Pravastatin (Pravachol), Simvastatin (Zocor), Others)
8.2.1.1. Atorvastatin (Lipitor)
8.2.1.2. Cerivastatin (Baycol)
8.2.1.3. Fluvastatin (Lescol)
8.2.1.4. Lovastatin (Mevacor)
8.2.1.5. Pravastatin (Pravachol)
8.2.1.6. Simvastatin (Zocor)
8.2.1.7. Others
8.2.2. Bile acid sequestrants
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.2.3. Niacin
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2021
8.2.3.3. Market Forecast, 2022 - 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2021
8.2.3.5.1.2. Market
Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2021
8.2.3.5.2.2. Market
Forecast, 2022 - 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2021
8.2.3.5.3.2. Market
Forecast, 2022 - 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2021
8.2.3.5.4.2. Market
Forecast, 2022 - 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2021
8.2.3.5.5.2. Market
Forecast, 2022 - 2030
8.2.4. Icosapent ethyl
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2021
8.2.4.3. Market Forecast, 2022 - 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2021
8.2.4.5.1.2. Market
Forecast, 2022 - 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2021
8.2.4.5.2.2. Market
Forecast, 2022 - 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2021
8.2.4.5.3.2. Market
Forecast, 2022 - 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2021
8.2.4.5.4.2. Market
Forecast, 2022 - 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2021
8.2.4.5.5.2. Market
Forecast, 2022 - 2030
8.2.5. Bempedoic acid
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2021
8.2.5.3. Market Forecast, 2022 - 2030
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 - 2021
8.2.5.5.1.2. Market
Forecast, 2022 - 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2021
8.2.5.5.2.2. Market
Forecast, 2022 - 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2021
8.2.5.5.3.2. Market
Forecast, 2022 - 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2021
8.2.5.5.4.2. Market
Forecast, 2022 - 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 - 2021
8.2.5.5.5.2. Market
Forecast, 2022 - 2030
8.2.6. PCSK9 Inhibitors
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 - 2021
8.2.6.3. Market Forecast, 2022 - 2030
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market
Estimation, 2015 - 2021
8.2.6.5.1.2. Market
Forecast, 2022 - 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 - 2021
8.2.6.5.2.2. Market
Forecast, 2022 - 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market
Estimation, 2015 - 2021
8.2.6.5.3.2. Market
Forecast, 2022 - 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 - 2021
8.2.6.5.4.2. Market
Forecast, 2022 - 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market
Estimation, 2015 - 2021
8.2.6.5.5.2. Market
Forecast, 2022 - 2030
8.2.7. Others
8.2.7.1. Definition
8.2.7.2. Market Estimation and Penetration, 2015 - 2021
8.2.7.3. Market Forecast, 2022 - 2030
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.7.5. Regional Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market
Estimation, 2015 - 2021
8.2.7.5.1.2. Market
Forecast, 2022 - 2030
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2015 - 2021
8.2.7.5.2.2. Market
Forecast, 2022 - 2030
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market
Estimation, 2015 - 2021
8.2.7.5.3.2. Market
Forecast, 2022 - 2030
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market
Estimation, 2015 - 2021
8.2.7.5.4.2. Market
Forecast, 2022 - 2030
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market
Estimation, 2015 - 2021
8.2.7.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Drug Type
9. Global Lipid-Lowering Therapy Market Analysis and Forecasts, 2022
- 2030
9.1. Overview
9.2. Global Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
9.2.1. Oral
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Subcutenous
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Route or administration
10. Global Lipid-Lowering Therapy Market Analysis and Forecasts, 2022
- 2030
10.1. Overview
10.2. Global Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
10.2.1. 55 years or younger
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2.  56–60 years
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.2.3.  61–65 years
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.2.4. 66–70 years
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 - 2030
10.2.5.  71–75 years
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2021
10.2.5.3. Market Forecast, 2022 - 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2021
10.2.5.5.1.2. Market
Forecast, 2022 - 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2021
10.2.5.5.2.2. Market
Forecast, 2022 - 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2021
10.2.5.5.3.2. Market
Forecast, 2022 - 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2021
10.2.5.5.4.2. Market
Forecast, 2022 - 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2021
10.2.5.5.5.2. Market
Forecast, 2022 - 2030
10.2.6. Older than 75 years
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 - 2021
10.2.6.3. Market Forecast, 2022 - 2030
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market
Estimation, 2015 - 2021
10.2.6.5.1.2. Market
Forecast, 2022 - 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 - 2021
10.2.6.5.2.2. Market
Forecast, 2022 - 2030
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market
Estimation, 2015 - 2021
10.2.6.5.3.2. Market
Forecast, 2022 - 2030
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 - 2021
10.2.6.5.4.2. Market
Forecast, 2022 - 2030
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market
Estimation, 2015 - 2021
10.2.6.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Age Group
11. North America Lipid-Lowering Therapy Market Analysis and
Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North America Lipid-Lowering Therapy Market Revenue (US$ Mn)
11.2. North America Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug Type
11.2.1. Statins
11.2.1.1. Atorvastatin (Lipitor)
11.2.1.2. Cerivastatin (Baycol)
11.2.1.3. Fluvastatin (Lescol)
11.2.1.4. Lovastatin (Mevacor)
11.2.1.5. Pravastatin (Pravachol)
11.2.1.6. Simvastatin (Zocor)
11.2.1.7. Others
11.2.2. Bile acid sequestrants
11.2.3. Niacin
11.2.4. Icosapent ethyl
11.2.5. Bempedoic acid
11.2.6. PCSK9 Inhibitors
11.2.7. Others
11.3. North America Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Route or administration
11.3.1. Oral
11.3.2. Subcutenous
11.4. North America Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Age Group
11.4.1. 55 years or younger
11.4.2.  56–60 years
11.4.3.  61–65 years
11.4.4. 66–70 years
11.4.5.  71–75 years
11.4.6. Older than 75 years
11.5. North America Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
11.5.1.1.1. Statins
11.5.1.1.1.1. Atorvastatin
(Lipitor)
11.5.1.1.1.2. Cerivastatin
(Baycol)
11.5.1.1.1.3. Fluvastatin
(Lescol)
11.5.1.1.1.4. Lovastatin
(Mevacor)
11.5.1.1.1.5. Pravastatin
(Pravachol)
11.5.1.1.1.6. Simvastatin
(Zocor)
11.5.1.1.1.7. Others
11.5.1.1.2. Bile acid sequestrants
11.5.1.1.3. Niacin
11.5.1.1.4. Icosapent ethyl
11.5.1.1.5. Bempedoic acid
11.5.1.1.6. PCSK9 Inhibitors
11.5.1.1.7. Others
11.5.1.2. U.S Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
11.5.1.2.1. Oral
11.5.1.2.2. Subcutenous
11.5.1.3. U.S Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
11.5.1.3.1. 55 years or younger
11.5.1.3.2.  56–60 years
11.5.1.3.3.  61–65 years
11.5.1.3.4. 66–70 years
11.5.1.3.5.  71–75 years
11.5.1.3.6. Older than 75 years
11.5.2. Canada
11.5.2.1. Canada Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
11.5.2.1.1. Statins
11.5.2.1.1.1. Atorvastatin
(Lipitor)
11.5.2.1.1.2. Cerivastatin
(Baycol)
11.5.2.1.1.3. Fluvastatin
(Lescol)
11.5.2.1.1.4. Lovastatin
(Mevacor)
11.5.2.1.1.5. Pravastatin
(Pravachol)
11.5.2.1.1.6. Simvastatin
(Zocor)
11.5.2.1.1.7. Others
11.5.2.1.2. Bile acid sequestrants
11.5.2.1.3. Niacin
11.5.2.1.4. Icosapent ethyl
11.5.2.1.5. Bempedoic acid
11.5.2.1.6. PCSK9 Inhibitors
11.5.2.1.7. Others
11.5.2.2. Canada Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
11.5.2.2.1. Oral
11.5.2.2.2. Subcutenous
11.5.2.3. Canada Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
11.5.2.3.1. 55 years or younger
11.5.2.3.2.  56–60 years
11.5.2.3.3.  61–65 years
11.5.2.3.4. 66–70 years
11.5.2.3.5.  71–75 years
11.5.2.3.6. Older than 75 years
11.5.3. Mexico
11.5.3.1. Mexico Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
11.5.3.1.1. Statins
11.5.3.1.1.1. Atorvastatin
(Lipitor)
11.5.3.1.1.2. Cerivastatin
(Baycol)
11.5.3.1.1.3. Fluvastatin
(Lescol)
11.5.3.1.1.4. Lovastatin
(Mevacor)
11.5.3.1.1.5. Pravastatin
(Pravachol)
11.5.3.1.1.6. Simvastatin
(Zocor)
11.5.3.1.1.7. Others
11.5.3.1.2. Bile acid sequestrants
11.5.3.1.3. Niacin
11.5.3.1.4. Icosapent ethyl
11.5.3.1.5. Bempedoic acid
11.5.3.1.6. PCSK9 Inhibitors
11.5.3.1.7. Others
11.5.3.2. Mexico Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
11.5.3.2.1. Oral
11.5.3.2.2. Subcutenous
11.5.3.3. Mexico Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
11.5.3.3.1. 55 years or younger
11.5.3.3.2.  56–60 years
11.5.3.3.3.  61–65 years
11.5.3.3.4. 66–70 years
11.5.3.3.5.  71–75 years
11.5.3.3.6. Older than 75 years
11.5.4. Rest of North America
11.5.4.1. Rest of North America Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Drug Type
11.5.4.1.1. Statins
11.5.4.1.1.1. Atorvastatin
(Lipitor)
11.5.4.1.1.2. Cerivastatin
(Baycol)
11.5.4.1.1.3. Fluvastatin
(Lescol)
11.5.4.1.1.4. Lovastatin
(Mevacor)
11.5.4.1.1.5. Pravastatin
(Pravachol)
11.5.4.1.1.6. Simvastatin
(Zocor)
11.5.4.1.1.7. Others
11.5.4.1.2. Bile acid sequestrants
11.5.4.1.3. Niacin
11.5.4.1.4. Icosapent ethyl
11.5.4.1.5. Bempedoic acid
11.5.4.1.6. PCSK9 Inhibitors
11.5.4.1.7. Others
11.5.4.2. Rest of North America Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Route or administration
11.5.4.2.1. Oral
11.5.4.2.2. Subcutenous
11.5.4.3. Rest of North America Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Age Group
11.5.4.3.1. 55 years or younger
11.5.4.3.2.  56–60 years
11.5.4.3.3.  61–65 years
11.5.4.3.4. 66–70 years
11.5.4.3.5.  71–75 years
11.5.4.3.6. Older than 75 years
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Drug Type
11.6.3. By Route or administration
11.6.4. By Age Group
12. Europe Lipid-Lowering Therapy Market Analysis and Forecasts, 2022
- 2030
12.1. Overview
12.1.1. Europe Lipid-Lowering Therapy Market Revenue (US$ Mn)
12.2. Europe Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.2.1. Statins
12.2.1.1. Atorvastatin (Lipitor)
12.2.1.2. Cerivastatin (Baycol)
12.2.1.3. Fluvastatin (Lescol)
12.2.1.4. Lovastatin (Mevacor)
12.2.1.5. Pravastatin (Pravachol)
12.2.1.6. Simvastatin (Zocor)
12.2.1.7. Others
12.2.2. Bile acid sequestrants
12.2.3. Niacin
12.2.4. Icosapent ethyl
12.2.5. Bempedoic acid
12.2.6. PCSK9 Inhibitors
12.2.7. Others
12.3. Europe Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
12.3.1. Oral
12.3.2. Subcutenous
12.4. Europe Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
12.4.1. 55 years or younger
12.4.2.  56–60 years
12.4.3.  61–65 years
12.4.4. 66–70 years
12.4.5.  71–75 years
12.4.6. Older than 75 years
12.5. Europe Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.1. France
12.5.1.1. France Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.5.1.1.1. Statins
12.5.1.1.1.1. Atorvastatin
(Lipitor)
12.5.1.1.1.2. Cerivastatin
(Baycol)
12.5.1.1.1.3. Fluvastatin
(Lescol)
12.5.1.1.1.4. Lovastatin
(Mevacor)
12.5.1.1.1.5. Pravastatin
(Pravachol)
12.5.1.1.1.6. Simvastatin
(Zocor)
12.5.1.1.1.7. Others
12.5.1.1.2. Bile acid sequestrants
12.5.1.1.3. Niacin
12.5.1.1.4. Icosapent ethyl
12.5.1.1.5. Bempedoic acid
12.5.1.1.6. PCSK9 Inhibitors
12.5.1.1.7. Others
12.5.1.2. France Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
12.5.1.2.1. Oral
12.5.1.2.2. Subcutenous
12.5.1.3. France Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
12.5.1.3.1. 55 years or younger
12.5.1.3.2.  56–60 years
12.5.1.3.3.  61–65 years
12.5.1.3.4. 66–70 years
12.5.1.3.5.  71–75 years
12.5.1.3.6. Older than 75 years
12.5.2. The UK
12.5.2.1. The UK Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.5.2.1.1. Statins
12.5.2.1.1.1. Atorvastatin
(Lipitor)
12.5.2.1.1.2. Cerivastatin
(Baycol)
12.5.2.1.1.3. Fluvastatin
(Lescol)
12.5.2.1.1.4. Lovastatin
(Mevacor)
12.5.2.1.1.5. Pravastatin
(Pravachol)
12.5.2.1.1.6. Simvastatin
(Zocor)
12.5.2.1.1.7. Others
12.5.2.1.2. Bile acid sequestrants
12.5.2.1.3. Niacin
12.5.2.1.4. Icosapent ethyl
12.5.2.1.5. Bempedoic acid
12.5.2.1.6. PCSK9 Inhibitors
12.5.2.1.7. Others
12.5.2.2. The UK Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
12.5.2.2.1. Oral
12.5.2.2.2. Subcutenous
12.5.2.3. The UK Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
12.5.2.3.1. 55 years or younger
12.5.2.3.2.  56–60 years
12.5.2.3.3.  61–65 years
12.5.2.3.4. 66–70 years
12.5.2.3.5.  71–75 years
12.5.2.3.6. Older than 75 years
12.5.3. Spain
12.5.3.1. Spain Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.5.3.1.1. Statins
12.5.3.1.1.1. Atorvastatin
(Lipitor)
12.5.3.1.1.2. Cerivastatin
(Baycol)
12.5.3.1.1.3. Fluvastatin
(Lescol)
12.5.3.1.1.4. Lovastatin
(Mevacor)
12.5.3.1.1.5. Pravastatin
(Pravachol)
12.5.3.1.1.6. Simvastatin
(Zocor)
12.5.3.1.1.7. Others
12.5.3.1.2. Bile acid sequestrants
12.5.3.1.3. Niacin
12.5.3.1.4. Icosapent ethyl
12.5.3.1.5. Bempedoic acid
12.5.3.1.6. PCSK9 Inhibitors
12.5.3.1.7. Others
12.5.3.2. Spain Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
12.5.3.2.1. Oral
12.5.3.2.2. Subcutenous
12.5.3.3. Spain Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
12.5.3.3.1. 55 years or younger
12.5.3.3.2.  56–60 years
12.5.3.3.3.  61–65 years
12.5.3.3.4. 66–70 years
12.5.3.3.5.  71–75 years
12.5.3.3.6. Older than 75 years
12.5.4. Germany
12.5.4.1. Germany Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.5.4.1.1. Statins
12.5.4.1.1.1. Atorvastatin
(Lipitor)
12.5.4.1.1.2. Cerivastatin
(Baycol)
12.5.4.1.1.3. Fluvastatin
(Lescol)
12.5.4.1.1.4. Lovastatin
(Mevacor)
12.5.4.1.1.5. Pravastatin
(Pravachol)
12.5.4.1.1.6. Simvastatin
(Zocor)
12.5.4.1.1.7. Others
12.5.4.1.2. Bile acid sequestrants
12.5.4.1.3. Niacin
12.5.4.1.4. Icosapent ethyl
12.5.4.1.5. Bempedoic acid
12.5.4.1.6. PCSK9 Inhibitors
12.5.4.1.7. Others
12.5.4.2. Germany Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
12.5.4.2.1. Oral
12.5.4.2.2. Subcutenous
12.5.4.3. Germany Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
12.5.4.3.1. 55 years or younger
12.5.4.3.2.  56–60 years
12.5.4.3.3.  61–65 years
12.5.4.3.4. 66–70 years
12.5.4.3.5.  71–75 years
12.5.4.3.6. Older than 75 years
12.5.5. Italy
12.5.5.1. Italy Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
12.5.5.1.1. Statins
12.5.5.1.1.1. Atorvastatin
(Lipitor)
12.5.5.1.1.2. Cerivastatin
(Baycol)
12.5.5.1.1.3. Fluvastatin
(Lescol)
12.5.5.1.1.4. Lovastatin
(Mevacor)
12.5.5.1.1.5. Pravastatin
(Pravachol)
12.5.5.1.1.6. Simvastatin
(Zocor)
12.5.5.1.1.7. Others
12.5.5.1.2. Bile acid sequestrants
12.5.5.1.3. Niacin
12.5.5.1.4. Icosapent ethyl
12.5.5.1.5. Bempedoic acid
12.5.5.1.6. PCSK9 Inhibitors
12.5.5.1.7. Others
12.5.5.2. Italy Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
12.5.5.2.1. Oral
12.5.5.2.2. Subcutenous
12.5.5.3. Italy Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
12.5.5.3.1. 55 years or younger
12.5.5.3.2.  56–60 years
12.5.5.3.3.  61–65 years
12.5.5.3.4. 66–70 years
12.5.5.3.5.  71–75 years
12.5.5.3.6. Older than 75 years
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Lipid-Lowering Therapy Market Revenue (US$
Mn) and Forecasts, By Drug Type
12.5.6.1.1. Statins
12.5.6.1.1.1. Atorvastatin
(Lipitor)
12.5.6.1.1.2. Cerivastatin
(Baycol)
12.5.6.1.1.3. Fluvastatin
(Lescol)
12.5.6.1.1.4. Lovastatin
(Mevacor)
12.5.6.1.1.5. Pravastatin
(Pravachol)
12.5.6.1.1.6. Simvastatin
(Zocor)
12.5.6.1.1.7. Others
12.5.6.1.2. Bile acid sequestrants
12.5.6.1.3. Niacin
12.5.6.1.4. Icosapent ethyl
12.5.6.1.5. Bempedoic acid
12.5.6.1.6. PCSK9 Inhibitors
12.5.6.1.7. Others
12.5.6.2. Nordic Countries Lipid-Lowering Therapy Market Revenue (US$
Mn) and Forecasts, By Route or administration
12.5.6.2.1. Oral
12.5.6.2.2. Subcutenous
12.5.6.3. Nordic Countries Lipid-Lowering Therapy Market Revenue (US$
Mn) and Forecasts, By Age Group
12.5.6.3.1. 55 years or younger
12.5.6.3.2.  56–60 years
12.5.6.3.3.  61–65 years
12.5.6.3.4. 66–70 years
12.5.6.3.5.  71–75 years
12.5.6.3.6. Older than 75 years
12.5.6.4. Nordic Countries Lipid-Lowering Therapy Market Revenue (US$
Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug Type
12.5.7.1.1. Statins
12.5.7.1.1.1. Atorvastatin
(Lipitor)
12.5.7.1.1.2. Cerivastatin
(Baycol)
12.5.7.1.1.3. Fluvastatin
(Lescol)
12.5.7.1.1.4. Lovastatin
(Mevacor)
12.5.7.1.1.5. Pravastatin
(Pravachol)
12.5.7.1.1.6. Simvastatin
(Zocor)
12.5.7.1.1.7. Others
12.5.7.1.2. Bile acid sequestrants
12.5.7.1.3. Niacin
12.5.7.1.4. Icosapent ethyl
12.5.7.1.5. Bempedoic acid
12.5.7.1.6. PCSK9 Inhibitors
12.5.7.1.7. Others
12.5.7.2. Benelux Union Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Route or administration
12.5.7.2.1. Oral
12.5.7.2.2. Subcutenous
12.5.7.3. Benelux Union Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Age Group
12.5.7.3.1. 55 years or younger
12.5.7.3.2.  56–60 years
12.5.7.3.3.  61–65 years
12.5.7.3.4. 66–70 years
12.5.7.3.5.  71–75 years
12.5.7.3.6. Older than 75 years
12.5.7.4. Benelux Union Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug Type
12.5.8.1.1. Statins
12.5.8.1.1.1. Atorvastatin
(Lipitor)
12.5.8.1.1.2. Cerivastatin
(Baycol)
12.5.8.1.1.3. Fluvastatin
(Lescol)
12.5.8.1.1.4. Lovastatin
(Mevacor)
12.5.8.1.1.5. Pravastatin
(Pravachol)
12.5.8.1.1.6. Simvastatin
(Zocor)
12.5.8.1.1.7. Others
12.5.8.1.2. Bile acid sequestrants
12.5.8.1.3. Niacin
12.5.8.1.4. Icosapent ethyl
12.5.8.1.5. Bempedoic acid
12.5.8.1.6. PCSK9 Inhibitors
12.5.8.1.7. Others
12.5.8.2. Rest of Europe Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Route or administration
12.5.8.2.1. Oral
12.5.8.2.2. Subcutenous
12.5.8.3. Rest of Europe Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Age Group
12.5.8.3.1. 55 years or younger
12.5.8.3.2.  56–60 years
12.5.8.3.3.  61–65 years
12.5.8.3.4. 66–70 years
12.5.8.3.5.  71–75 years
12.5.8.3.6. Older than 75 years
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Drug Type
12.6.3. By Route or administration
12.6.4. By Age Group
13. Asia Pacific Lipid-Lowering Therapy Market Analysis and
Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia Pacific Lipid-Lowering Therapy Market Revenue (US$ Mn)
13.2. Asia Pacific Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug Type
13.2.1. Statins
13.2.1.1. Atorvastatin (Lipitor)
13.2.1.2. Cerivastatin (Baycol)
13.2.1.3. Fluvastatin (Lescol)
13.2.1.4. Lovastatin (Mevacor)
13.2.1.5. Pravastatin (Pravachol)
13.2.1.6. Simvastatin (Zocor)
13.2.1.7. Others
13.2.2. Bile acid sequestrants
13.2.3. Niacin
13.2.4. Icosapent ethyl
13.2.5. Bempedoic acid
13.2.6. PCSK9 Inhibitors
13.2.7. Others
13.3. Asia Pacific Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Route or administration
13.3.1. Oral
13.3.2. Subcutenous
13.4. Asia Pacific Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Age Group
13.4.1. 55 years or younger
13.4.2.  56–60 years
13.4.3.  61–65 years
13.4.4. 66–70 years
13.4.5.  71–75 years
13.4.6. Older than 75 years
13.5. Asia Pacific Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
13.5.1. China
13.5.1.1. China Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
13.5.1.1.1. Statins
13.5.1.1.1.1. Atorvastatin
(Lipitor)
13.5.1.1.1.2. Cerivastatin
(Baycol)
13.5.1.1.1.3. Fluvastatin
(Lescol)
13.5.1.1.1.4. Lovastatin
(Mevacor)
13.5.1.1.1.5. Pravastatin
(Pravachol)
13.5.1.1.1.6. Simvastatin
(Zocor)
13.5.1.1.1.7. Others
13.5.1.1.2. Bile acid sequestrants
13.5.1.1.3. Niacin
13.5.1.1.4. Icosapent ethyl
13.5.1.1.5. Bempedoic acid
13.5.1.1.6. PCSK9 Inhibitors
13.5.1.1.7. Others
13.5.1.2. China Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
13.5.1.2.1. Oral
13.5.1.2.2. Subcutenous
13.5.1.3. China Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.5.1.3.1. 55 years or younger
13.5.1.3.2.  56–60 years
13.5.1.3.3.  61–65 years
13.5.1.3.4. 66–70 years
13.5.1.3.5.  71–75 years
13.5.1.3.6. Older than 75 years
13.5.2. Japan
13.5.2.1. Japan Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
13.5.2.1.1. Statins
13.5.2.1.1.1. Atorvastatin
(Lipitor)
13.5.2.1.1.2. Cerivastatin
(Baycol)
13.5.2.1.1.3. Fluvastatin
(Lescol)
13.5.2.1.1.4. Lovastatin
(Mevacor)
13.5.2.1.1.5. Pravastatin
(Pravachol)
13.5.2.1.1.6. Simvastatin
(Zocor)
13.5.2.1.1.7. Others
13.5.2.1.2. Bile acid sequestrants
13.5.2.1.3. Niacin
13.5.2.1.4. Icosapent ethyl
13.5.2.1.5. Bempedoic acid
13.5.2.1.6. PCSK9 Inhibitors
13.5.2.1.7. Others
13.5.2.2. Japan Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
13.5.2.2.1. Oral
13.5.2.2.2. Subcutenous
13.5.2.3. Japan Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.5.2.3.1. 55 years or younger
13.5.2.3.2.  56–60 years
13.5.2.3.3.  61–65 years
13.5.2.3.4. 66–70 years
13.5.2.3.5.  71–75 years
13.5.2.3.6. Older than 75 years
13.5.3. India
13.5.3.1. India Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
13.5.3.1.1. Statins
13.5.3.1.1.1. Atorvastatin
(Lipitor)
13.5.3.1.1.2. Cerivastatin
(Baycol)
13.5.3.1.1.3. Fluvastatin
(Lescol)
13.5.3.1.1.4. Lovastatin
(Mevacor)
13.5.3.1.1.5. Pravastatin
(Pravachol)
13.5.3.1.1.6. Simvastatin
(Zocor)
13.5.3.1.1.7. Others
13.5.3.1.2. Bile acid sequestrants
13.5.3.1.3. Niacin
13.5.3.1.4. Icosapent ethyl
13.5.3.1.5. Bempedoic acid
13.5.3.1.6. PCSK9 Inhibitors
13.5.3.1.7. Others
13.5.3.2. India Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
13.5.3.2.1. Oral
13.5.3.2.2. Subcutenous
13.5.3.3. India Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.5.3.3.1. 55 years or younger
13.5.3.3.2.  56–60 years
13.5.3.3.3.  61–65 years
13.5.3.3.4. 66–70 years
13.5.3.3.5.  71–75 years
13.5.3.3.6. Older than 75 years
13.5.4. New Zealand
13.5.4.1. New Zealand Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
13.5.4.1.1. Statins
13.5.4.1.1.1. Atorvastatin
(Lipitor)
13.5.4.1.1.2. Cerivastatin
(Baycol)
13.5.4.1.1.3. Fluvastatin
(Lescol)
13.5.4.1.1.4. Lovastatin
(Mevacor)
13.5.4.1.1.5. Pravastatin
(Pravachol)
13.5.4.1.1.6. Simvastatin
(Zocor)
13.5.4.1.1.7. Others
13.5.4.1.2. Bile acid sequestrants
13.5.4.1.3. Niacin
13.5.4.1.4. Icosapent ethyl
13.5.4.1.5. Bempedoic acid
13.5.4.1.6. PCSK9 Inhibitors
13.5.4.1.7. Others
13.5.4.2. New Zealand Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
13.5.4.2.1. Oral
13.5.4.2.2. Subcutenous
13.5.4.3. New Zealand Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.5.4.3.1. 55 years or younger
13.5.4.3.2.  56–60 years
13.5.4.3.3.  61–65 years
13.5.4.3.4. 66–70 years
13.5.4.3.5.  71–75 years
13.5.4.3.6. Older than 75 years
13.5.5. Australia
13.5.5.1. Australia Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
13.5.5.1.1. Statins
13.5.5.1.1.1. Atorvastatin
(Lipitor)
13.5.5.1.1.2. Cerivastatin
(Baycol)
13.5.5.1.1.3. Fluvastatin
(Lescol)
13.5.5.1.1.4. Lovastatin
(Mevacor)
13.5.5.1.1.5. Pravastatin
(Pravachol)
13.5.5.1.1.6. Simvastatin
(Zocor)
13.5.5.1.1.7. Others
13.5.5.1.2. Bile acid sequestrants
13.5.5.1.3. Niacin
13.5.5.1.4. Icosapent ethyl
13.5.5.1.5. Bempedoic acid
13.5.5.1.6. PCSK9 Inhibitors
13.5.5.1.7. Others
13.5.5.2. Australia Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
13.5.5.2.1. Oral
13.5.5.2.2. Subcutenous
13.5.5.3. Australia Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.5.5.3.1. 55 years or younger
13.5.5.3.2.  56–60 years
13.5.5.3.3.  61–65 years
13.5.5.3.4. 66–70 years
13.5.5.3.5.  71–75 years
13.5.5.3.6. Older than 75 years
13.5.6. South Korea
13.5.6.1. South Korea Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
13.5.6.1.1. Statins
13.5.6.1.1.1. Atorvastatin
(Lipitor)
13.5.6.1.1.2. Cerivastatin
(Baycol)
13.5.6.1.1.3. Fluvastatin
(Lescol)
13.5.6.1.1.4. Lovastatin
(Mevacor)
13.5.6.1.1.5. Pravastatin
(Pravachol)
13.5.6.1.1.6. Simvastatin
(Zocor)
13.5.6.1.1.7. Others
13.5.6.1.2. Bile acid sequestrants
13.5.6.1.3. Niacin
13.5.6.1.4. Icosapent ethyl
13.5.6.1.5. Bempedoic acid
13.5.6.1.6. PCSK9 Inhibitors
13.5.6.1.7. Others
13.5.6.2. South Korea Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
13.5.6.2.1. Oral
13.5.6.2.2. Subcutenous
13.5.6.3. South Korea Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.5.6.3.1. 55 years or younger
13.5.6.3.2.  56–60 years
13.5.6.3.3.  61–65 years
13.5.6.3.4. 66–70 years
13.5.6.3.5.  71–75 years
13.5.6.3.6. Older than 75 years
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug Type
13.5.7.1.1. Statins
13.5.7.1.1.1. Atorvastatin
(Lipitor)
13.5.7.1.1.2. Cerivastatin
(Baycol)
13.5.7.1.1.3. Fluvastatin
(Lescol)
13.5.7.1.1.4. Lovastatin
(Mevacor)
13.5.7.1.1.5. Pravastatin
(Pravachol)
13.5.7.1.1.6. Simvastatin
(Zocor)
13.5.7.1.1.7. Others
13.5.7.1.2. Bile acid sequestrants
13.5.7.1.3. Niacin
13.5.7.1.4. Icosapent ethyl
13.5.7.1.5. Bempedoic acid
13.5.7.1.6. PCSK9 Inhibitors
13.5.7.1.7. Others
13.5.7.2. Southeast Asia Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Route or administration
13.5.7.2.1. Oral
13.5.7.2.2. Subcutenous
13.5.7.3. Southeast Asia Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Age Group
13.5.7.3.1. 55 years or younger
13.5.7.3.2.  56–60 years
13.5.7.3.3.  61–65 years
13.5.7.3.4. 66–70 years
13.5.7.3.5.  71–75 years
13.5.7.3.6. Older than 75 years
13.5.7.4. Southeast Asia Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Drug Type
13.5.8.1.1. Statins
13.5.8.1.1.1. Atorvastatin
(Lipitor)
13.5.8.1.1.2. Cerivastatin
(Baycol)
13.5.8.1.1.3. Fluvastatin
(Lescol)
13.5.8.1.1.4. Lovastatin
(Mevacor)
13.5.8.1.1.5. Pravastatin
(Pravachol)
13.5.8.1.1.6. Simvastatin
(Zocor)
13.5.8.1.1.7. Others
13.5.8.1.2. Bile acid sequestrants
13.5.8.1.3. Niacin
13.5.8.1.4. Icosapent ethyl
13.5.8.1.5. Bempedoic acid
13.5.8.1.6. PCSK9 Inhibitors
13.5.8.1.7. Others
13.5.8.2. Rest of Asia Pacific Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Route or administration
13.5.8.2.1. Oral
13.5.8.2.2. Subcutenous
13.5.8.3. Rest of Asia Pacific Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Age Group
13.5.8.3.1. 55 years or younger
13.5.8.3.2.  56–60 years
13.5.8.3.3.  61–65 years
13.5.8.3.4. 66–70 years
13.5.8.3.5.  71–75 years
13.5.8.3.6. Older than 75 years
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Drug Type
13.6.3. By Route or administration
13.6.4. By Age Group
14. Middle East and Africa Lipid-Lowering Therapy Market Analysis
and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle East and Africa Lipid-Lowering Therapy Market Revenue
(US$ Mn)
14.2. Middle East and Africa Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Drug Type
14.2.1. Statins
14.2.1.1. Atorvastatin (Lipitor)
14.2.1.2. Cerivastatin (Baycol)
14.2.1.3. Fluvastatin (Lescol)
14.2.1.4. Lovastatin (Mevacor)
14.2.1.5. Pravastatin (Pravachol)
14.2.1.6. Simvastatin (Zocor)
14.2.1.7. Others
14.2.2. Bile acid sequestrants
14.2.3. Niacin
14.2.4. Icosapent ethyl
14.2.5. Bempedoic acid
14.2.6. PCSK9 Inhibitors
14.2.7. Others
14.3. Middle East and Africa Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Route or administration
14.3.1. Oral
14.3.2. Subcutenous
14.4. Middle East and Africa Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Age Group
14.4.1. 55 years or younger
14.4.2.  56–60 years
14.4.3.  61–65 years
14.4.4. 66–70 years
14.4.5.  71–75 years
14.4.6. Older than 75 years
14.5. Middle East and Africa Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug Type
14.5.1.1.1. Statins
14.5.1.1.1.1. Atorvastatin
(Lipitor)
14.5.1.1.1.2. Cerivastatin
(Baycol)
14.5.1.1.1.3. Fluvastatin
(Lescol)
14.5.1.1.1.4. Lovastatin
(Mevacor)
14.5.1.1.1.5. Pravastatin
(Pravachol)
14.5.1.1.1.6. Simvastatin
(Zocor)
14.5.1.1.1.7. Others
14.5.1.1.2. Bile acid sequestrants
14.5.1.1.3. Niacin
14.5.1.1.4. Icosapent ethyl
14.5.1.1.5. Bempedoic acid
14.5.1.1.6. PCSK9 Inhibitors
14.5.1.1.7. Others
14.5.1.2. Saudi Arabia Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Route or administration
14.5.1.2.1. Oral
14.5.1.2.2. Subcutenous
14.5.1.3. Saudi Arabia Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Age Group
14.5.1.3.1. 55 years or younger
14.5.1.3.2.  56–60 years
14.5.1.3.3.  61–65 years
14.5.1.3.4. 66–70 years
14.5.1.3.5.  71–75 years
14.5.1.3.6. Older than 75 years
14.5.2. UAE
14.5.2.1. UAE Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
14.5.2.1.1. Statins
14.5.2.1.1.1. Atorvastatin
(Lipitor)
14.5.2.1.1.2. Cerivastatin
(Baycol)
14.5.2.1.1.3. Fluvastatin
(Lescol)
14.5.2.1.1.4. Lovastatin
(Mevacor)
14.5.2.1.1.5. Pravastatin
(Pravachol)
14.5.2.1.1.6. Simvastatin
(Zocor)
14.5.2.1.1.7. Others
14.5.2.1.2. Bile acid sequestrants
14.5.2.1.3. Niacin
14.5.2.1.4. Icosapent ethyl
14.5.2.1.5. Bempedoic acid
14.5.2.1.6. PCSK9 Inhibitors
14.5.2.1.7. Others
14.5.2.2. UAE Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
14.5.2.2.1. Oral
14.5.2.2.2. Subcutenous
14.5.2.3. UAE Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.5.2.3.1. 55 years or younger
14.5.2.3.2.  56–60 years
14.5.2.3.3.  61–65 years
14.5.2.3.4. 66–70 years
14.5.2.3.5.  71–75 years
14.5.2.3.6. Older than 75 years
14.5.3. Egypt
14.5.3.1. Egypt Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
14.5.3.1.1. Statins
14.5.3.1.1.1. Atorvastatin
(Lipitor)
14.5.3.1.1.2. Cerivastatin
(Baycol)
14.5.3.1.1.3. Fluvastatin
(Lescol)
14.5.3.1.1.4. Lovastatin
(Mevacor)
14.5.3.1.1.5. Pravastatin
(Pravachol)
14.5.3.1.1.6. Simvastatin
(Zocor)
14.5.3.1.1.7. Others
14.5.3.1.2. Bile acid sequestrants
14.5.3.1.3. Niacin
14.5.3.1.4. Icosapent ethyl
14.5.3.1.5. Bempedoic acid
14.5.3.1.6. PCSK9 Inhibitors
14.5.3.1.7. Others
14.5.3.2. Egypt Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
14.5.3.2.1. Oral
14.5.3.2.2. Subcutenous
14.5.3.3. Egypt Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.5.3.3.1. 55 years or younger
14.5.3.3.2.  56–60 years
14.5.3.3.3.  61–65 years
14.5.3.3.4. 66–70 years
14.5.3.3.5.  71–75 years
14.5.3.3.6. Older than 75 years
14.5.4. Kuwait
14.5.4.1. Kuwait Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
14.5.4.1.1. Statins
14.5.4.1.1.1. Atorvastatin
(Lipitor)
14.5.4.1.1.2. Cerivastatin
(Baycol)
14.5.4.1.1.3. Fluvastatin
(Lescol)
14.5.4.1.1.4. Lovastatin
(Mevacor)
14.5.4.1.1.5. Pravastatin
(Pravachol)
14.5.4.1.1.6. Simvastatin
(Zocor)
14.5.4.1.1.7. Others
14.5.4.1.2. Bile acid sequestrants
14.5.4.1.3. Niacin
14.5.4.1.4. Icosapent ethyl
14.5.4.1.5. Bempedoic acid
14.5.4.1.6. PCSK9 Inhibitors
14.5.4.1.7. Others
14.5.4.2. Kuwait Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
14.5.4.2.1. Oral
14.5.4.2.2. Subcutenous
14.5.4.3. Kuwait Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.5.4.3.1. 55 years or younger
14.5.4.3.2.  56–60 years
14.5.4.3.3.  61–65 years
14.5.4.3.4. 66–70 years
14.5.4.3.5.  71–75 years
14.5.4.3.6. Older than 75 years
14.5.5. South Africa
14.5.5.1. South Africa Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug Type
14.5.5.1.1. Statins
14.5.5.1.1.1. Atorvastatin
(Lipitor)
14.5.5.1.1.2. Cerivastatin
(Baycol)
14.5.5.1.1.3. Fluvastatin
(Lescol)
14.5.5.1.1.4. Lovastatin
(Mevacor)
14.5.5.1.1.5. Pravastatin
(Pravachol)
14.5.5.1.1.6. Simvastatin
(Zocor)
14.5.5.1.1.7. Others
14.5.5.1.2. Bile acid sequestrants
14.5.5.1.3. Niacin
14.5.5.1.4. Icosapent ethyl
14.5.5.1.5. Bempedoic acid
14.5.5.1.6. PCSK9 Inhibitors
14.5.5.1.7. Others
14.5.5.2. South Africa Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Route or administration
14.5.5.2.1. Oral
14.5.5.2.2. Subcutenous
14.5.5.3. South Africa Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Age Group
14.5.5.3.1. 55 years or younger
14.5.5.3.2.  56–60 years
14.5.5.3.3.  61–65 years
14.5.5.3.4. 66–70 years
14.5.5.3.5.  71–75 years
14.5.5.3.6. Older than 75 years
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Lipid-Lowering Therapy Market
Revenue (US$ Mn) and Forecasts, By Drug Type
14.5.6.1.1. Statins
14.5.6.1.1.1. Atorvastatin
(Lipitor)
14.5.6.1.1.2. Cerivastatin
(Baycol)
14.5.6.1.1.3. Fluvastatin
(Lescol)
14.5.6.1.1.4. Lovastatin
(Mevacor)
14.5.6.1.1.5. Pravastatin
(Pravachol)
14.5.6.1.1.6. Simvastatin
(Zocor)
14.5.6.1.1.7. Others
14.5.6.1.2. Bile acid sequestrants
14.5.6.1.3. Niacin
14.5.6.1.4. Icosapent ethyl
14.5.6.1.5. Bempedoic acid
14.5.6.1.6. PCSK9 Inhibitors
14.5.6.1.7. Others
14.5.6.2. Rest of Middle East & Africa Lipid-Lowering Therapy Market
Revenue (US$ Mn) and Forecasts, By Route or administration
14.5.6.2.1. Oral
14.5.6.2.2. Subcutenous
14.5.6.3. Rest of Middle East & Africa Lipid-Lowering Therapy Market
Revenue (US$ Mn) and Forecasts, By Age Group
14.5.6.3.1. 55 years or younger
14.5.6.3.2.  56–60 years
14.5.6.3.3.  61–65 years
14.5.6.3.4. 66–70 years
14.5.6.3.5.  71–75 years
14.5.6.3.6. Older than 75 years
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Drug Type
14.6.3. By Route or administration
14.6.4. By Age Group
15. Latin America Lipid-Lowering Therapy Market Analysis and
Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin America Lipid-Lowering Therapy Market Revenue (US$ Mn)
15.2. Latin America Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Drug Type
15.2.1. Statins
15.2.1.1. Atorvastatin (Lipitor)
15.2.1.2. Cerivastatin (Baycol)
15.2.1.3. Fluvastatin (Lescol)
15.2.1.4. Lovastatin (Mevacor)
15.2.1.5. Pravastatin (Pravachol)
15.2.1.6. Simvastatin (Zocor)
15.2.1.7. Others
15.2.2. Bile acid sequestrants
15.2.3. Niacin
15.2.4. Icosapent ethyl
15.2.5. Bempedoic acid
15.2.6. PCSK9 Inhibitors
15.2.7. Others
15.3. Latin America Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Route or administration
15.3.1. Oral
15.3.2. Subcutenous
15.4. Latin America Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Age Group
15.4.1. 55 years or younger
15.4.2.  56–60 years
15.4.3.  61–65 years
15.4.4. 66–70 years
15.4.5.  71–75 years
15.4.6. Older than 75 years
15.5. Latin America Lipid-Lowering Therapy Market Revenue (US$ Mn)
and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
15.5.1.1.1. Statins
15.5.1.1.1.1. Atorvastatin
(Lipitor)
15.5.1.1.1.2. Cerivastatin
(Baycol)
15.5.1.1.1.3. Fluvastatin
(Lescol)
15.5.1.1.1.4. Lovastatin
(Mevacor)
15.5.1.1.1.5. Pravastatin
(Pravachol)
15.5.1.1.1.6. Simvastatin
(Zocor)
15.5.1.1.1.7. Others
15.5.1.1.2. Bile acid sequestrants
15.5.1.1.3. Niacin
15.5.1.1.4. Icosapent ethyl
15.5.1.1.5. Bempedoic acid
15.5.1.1.6. PCSK9 Inhibitors
15.5.1.1.7. Others
15.5.1.2. Brazil Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
15.5.1.2.1. Oral
15.5.1.2.2. Subcutenous
15.5.1.3. Brazil Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
15.5.1.3.1. 55 years or younger
15.5.1.3.2.  56–60 years
15.5.1.3.3.  61–65 years
15.5.1.3.4. 66–70 years
15.5.1.3.5.  71–75 years
15.5.1.3.6. Older than 75 years
15.5.2. Argentina
15.5.2.1. Argentina Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug Type
15.5.2.1.1. Statins
15.5.2.1.1.1. Atorvastatin
(Lipitor)
15.5.2.1.1.2. Cerivastatin
(Baycol)
15.5.2.1.1.3. Fluvastatin
(Lescol)
15.5.2.1.1.4. Lovastatin
(Mevacor)
15.5.2.1.1.5. Pravastatin
(Pravachol)
15.5.2.1.1.6. Simvastatin
(Zocor)
15.5.2.1.1.7. Others
15.5.2.1.2. Bile acid sequestrants
15.5.2.1.3. Niacin
15.5.2.1.4. Icosapent ethyl
15.5.2.1.5. Bempedoic acid
15.5.2.1.6. PCSK9 Inhibitors
15.5.2.1.7. Others
15.5.2.2. Argentina Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Route or administration
15.5.2.2.1. Oral
15.5.2.2.2. Subcutenous
15.5.2.3. Argentina Lipid-Lowering Therapy Market Revenue (US$ Mn) and
Forecasts, By Age Group
15.5.2.3.1. 55 years or younger
15.5.2.3.2.  56–60 years
15.5.2.3.3.  61–65 years
15.5.2.3.4. 66–70 years
15.5.2.3.5.  71–75 years
15.5.2.3.6. Older than 75 years
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Drug Type
15.5.3.1.1. Statins
15.5.3.1.1.1. Atorvastatin
(Lipitor)
15.5.3.1.1.2. Cerivastatin
(Baycol)
15.5.3.1.1.3. Fluvastatin
(Lescol)
15.5.3.1.1.4. Lovastatin
(Mevacor)
15.5.3.1.1.5. Pravastatin
(Pravachol)
15.5.3.1.1.6. Simvastatin
(Zocor)
15.5.3.1.1.7. Others
15.5.3.1.2. Bile acid sequestrants
15.5.3.1.3. Niacin
15.5.3.1.4. Icosapent ethyl
15.5.3.1.5. Bempedoic acid
15.5.3.1.6. PCSK9 Inhibitors
15.5.3.1.7. Others
15.5.3.2. Rest of Latin America Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Route or administration
15.5.3.2.1. Oral
15.5.3.2.2. Subcutenous
15.5.3.3. Rest of Latin America Lipid-Lowering Therapy Market Revenue
(US$ Mn) and Forecasts, By Age Group
15.5.3.3.1. 55 years or younger
15.5.3.3.2.  56–60 years
15.5.3.3.3.  61–65 years
15.5.3.3.4. 66–70 years
15.5.3.3.5.  71–75 years
15.5.3.3.6. Older than 75 years
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Drug Type
15.6.3. By Route or administration
15.6.4. By Age Group
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2021
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Akums Drugs & Pharmaceuticals Ltd
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Alnylam Pharmaceuticals, Inc
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. Amgen Inc.
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. AstraZeneca
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Merck & CoÂ
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Novartis AG
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Regeneron Pharmaceuticals Inc.
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. Sun Pharmaceutical Industries
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. Other Market Participants
18. Key Findings
Note: This ToC is tentative and can be changed
according to the research study conducted
during
the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.